Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Transcutaneous Pulsed Radiofrequency Targeting the Tibial Nerve Versus Radial Extracorporeal Shock Wave Therapy for Painful Calcaneal Spur: a Randomized Controlled Trial

6 november 2026 bijgewerkt door: Halil Ibrahim Altun

Heel pain is a common musculoskeletal complaint that can substantially impair daily activities and reduce patients' quality of life. Calcaneal spurs are frequently associated with plantar heel pain, although the presence of a spur does not necessarily indicate that it is the direct source of symptoms. Treatment is generally conservative and may include activity modification, stretching exercises, orthoses, analgesics, and physical therapy modalities. However, some patients continue to experience symptoms despite these interventions.

Extracorporeal shock wave therapy (ESWT) is an established non-invasive treatment option for persistent plantar heel pain and plantar fasciopathy. It delivers acoustic pressure waves to the target tissue and is thought to exert its therapeutic effects through mechanotransduction, vascular responses, tissue remodeling, and modulation of nociceptive signaling.

Pulsed radiofrequency (PRF) is a neuromodulatory technique that delivers intermittent radiofrequency energy while limiting thermal tissue damage. Its proposed mechanisms include modulation of nociceptive transmission and neural signaling rather than intentional nerve destruction. Transcutaneous pulsed radiofrequency (TCPRF) provides a non-invasive approach by delivering radiofrequency energy through surface electrodes, without the need for needle insertion.

Although radiofrequency-based interventions and ESWT have been investigated separately in patients with painful calcaneal spurs and plantar heel pain, clinical evidence regarding TCPRF targeting the posterior tibial nerve remains limited. This randomized controlled trial compared the effects of TCPRF applied over the posterior tibial nerve with radial ESWT in patients with symptomatic calcaneal spurs. Pain intensity, foot-related function, and analgesic consumption were evaluated over a three-month follow-up period.

Studie Overzicht

Gedetailleerde beschrijving

This prospective, single-center, randomized controlled trial was conducted between September 2024 and April 2025 in the Pain Medicine and Physical Medicine and Rehabilitation departments of the University of Health Sciences Istanbul Kanuni Sultan Suleyman Training and Research Hospital. A total of 55 patients aged 18-65 years with symptomatic, radiologically confirmed calcaneal spurs who had not responded adequately to conservative treatment were enrolled.

Following confirmation of eligibility and provision of written informed consent, participants were assigned to one of two treatment groups using a computer-generated randomization sequence: the TCPRF group (n = 29) or the radial ESWT group (n = 26). The sample size calculation was performed using G*Power version 3.1.9.4, with a two-sided significance level of 0.05, statistical power of 90%, and an effect size of 0.85 based on pain intensity data from a previous randomized trial of TCPRF. The calculated minimum sample sizes were 28 participants for the TCPRF group and 24 for the ESWT group.

In the TCPRF group, treatment was administered by an experienced pain medicine specialist under standard monitoring, including non-invasive blood pressure measurement, pulse oximetry, and electrocardiography. Participants were placed in the supine position. A 45 × 98 mm transcutaneous electrode (FIAB SPA, Italy) was positioned at the ankle, posterior to the medial malleolus, along the course of the posterior tibial nerve and adjacent to the posterior tibial artery, which was identified by palpation. TCPRF was delivered at 80 V, 2 Hz, and a pulse duration of 20 ms for 8 minutes. The treatment was administered once weekly for a total of three sessions.

In the ESWT group, radial extracorporeal shock wave therapy was delivered using an electro-pneumatic device (Vibrolith Orto®). All sessions were administered by the same physiotherapist under the supervision of a physical medicine and rehabilitation specialist with at least 10 years of experience in ESWT prescription. Participants were positioned prone, and radial shock waves were applied to the calcaneal spur region using the following parameters: 10 Hz, 2,000 impulses, and 2.5 bar. Treatment was administered once weekly for a total of three sessions.

Participants in both groups received standardized instructions regarding a home exercise program that included foot and plantar fascia stretching exercises. Paracetamol was permitted as the only rescue analgesic during the follow-up period; the use of other analgesics, including non-steroidal anti-inflammatory drugs, was discouraged.

Treatment outcomes were assessed by an independent pain medicine specialist who was blinded to treatment allocation. Demographic and clinical data, including age, sex, body mass index, symptom duration, comorbidities, concomitant medical treatments, and the treated side, were recorded at baseline. Pain intensity was assessed using the Visual Analogue Scale (VAS), a 10-cm scale ranging from 0 (no pain) to 10 (the worst pain imaginable). Participants were asked to indicate their average heel pain during the preceding week. Foot-related function was evaluated using the Foot Function Index (FFI), a validated 23-item questionnaire comprising three domains: pain, disability, and activity limitation. Higher FFI scores indicate greater functional impairment. Mean daily paracetamol consumption was also recorded in milligrams per day.

VAS scores, FFI scores, and daily paracetamol consumption were evaluated at baseline (T0), one month (T1), and three months (T3) after treatment. The FFI was prespecified as the primary outcome, while VAS pain scores and mean daily paracetamol consumption were considered secondary outcomes.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

55

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Istanbul, Turkije (Türkiye), 34000
        • Kanuni Sultan Süleyman Training and Research Hospital

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 65 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria

Patients aged 18-65 years.

Patients diagnosed with calcaneal spur based on medical history, clinical examination, and radiological findings, who had not responded adequately to conservative treatment.

Patients who provided written informed consent to participate in the study.

Exclusion Criteria

Patients who had undergone any interventional procedure for calcaneal spur within the preceding 6 months.

Patients with morbid obesity (body mass index > 35 kg/m²).

Patients with advanced decompensated heart failure or an implanted cardiac pacemaker.

Patients with a known allergy to transcutaneous electrodes or pads.

Patients with skin infection at the ESWT application site or the transcutaneous electrode placement site.

Patients with metal implants.

Patients with circulatory disorders or skin lesions in the treatment area.

Patients unable to communicate adequately or maintain the required treatment position.

Patients with bleeding disorders.

Patients with active psychosis, progressive neurological deficits, or neuromuscular disorders.

Pregnant women.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Ander: Neuromodulatie van de achterste tibiale zenuw in de hielspoor (Epin Calcanei)

Instead of invasive application of PRF directly to the lesion area or nerve, transcutaneous pulsed radiofrequency (TCPRF) is applied noninvasively.

Ander: extracorporale schokgolftherapie (ESWT)

A shock wave is created together with sound and pressure waves. Changes at the cellular level with the shock wave include increased collagen production, increased blood flow in the applied area, acceleration of wound healing and cellular proliferation.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Tijdsspanne
Visual Analogue Scale
Tijdsspanne: three months
three months
Foot Function Index
Tijdsspanne: three months
three months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: halil ibrahim altun, specialist, Kanuni Sultan Süleyman Training and Research Hospital

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 september 2024

Primaire voltooiing (Werkelijk)

20 november 2024

Studie voltooiing (Werkelijk)

30 april 2025

Studieregistratiedata

Eerst ingediend

12 augustus 2024

Eerst ingediend dat voldeed aan de QC-criteria

14 augustus 2024

Eerst geplaatst (Werkelijk)

16 augustus 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

12 november 2026

Laatste update ingediend die voldeed aan QC-criteria

6 november 2026

Laatst geverifieerd

1 september 2025

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren